arrow_back Civic Audit
Share share

Global Strategy for Pandemic and Superbug Preparedness

This act aims to establish a global strategy to accelerate the development and availability of medical products needed during pandemics and to combat antibiotic-resistant bacteria. Through international cooperation, citizens can expect better preparedness for future health threats and faster access to medicines and vaccines.
Key points
International Cooperation: The U.S. government will seek support from other countries and organizations to jointly develop medicines and vaccines for pandemics and superbugs.
Faster Access to Products: The goal is to speed up research and market introduction of medical products, potentially meaning quicker access for citizens in times of threat.
Combating Resistant Bacteria: The act also addresses the issue of antibiotic-resistant bacteria, which is crucial for public health.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
Print number: 117_HR_9303
Sponsor: Rep. Levin, Mike [D-CA-49]
Process start date: 2022-11-15
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

SUPER BUGS Act of 2022

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_HR_9303.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2022-11-15.

What are the main provisions?

Key points include:

  • International Cooperation: The U.S. government will seek support from other countries and organizations to jointly develop medicines and vaccines for pandemics and superbugs.
  • Faster Access to Products: The goal is to speed up research and market introduction of medical products, potentially meaning quicker access for citizens in times of threat.
  • Combating Resistant Bacteria: The act also addresses the issue of antibiotic-resistant bacteria, which is crucial for public health.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Levin, Mike [D-CA-49].

What is the latest detailed status?

The latest detailed status is: Referred to the House Committee on Foreign Affairs.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-28.

What is the impact of this bill?

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge.

CATEGORIES

Health